Comparing the Antibody Response to COVID-19 Vaccination in Multiple Sclerosis Patients Treated With Ocrelizumab or Natalizumab
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Autoimmune Diseases
- Autoimmune Diseases of the Nervous System
- Demyelinating Autoimmune Diseases, CNS
- Demyelinating Diseases
- Immune System Diseases
- Multiple Sclerosis
- Nervous System Diseases
- Pathologic Processes
- Type
- Observational
- Design
- Observational Model: CohortTime Perspective: Prospective
Participation Requirements
- Age
- Between 18 years and 55 years
- Gender
- Both males and females
Description
The purpose of this study is to see if patients on ocrelizumab (Ocrevus) make antibodies in response to the coronavirus vaccine. Ocrelizumab depletes B-lymphocytes and has the potential to reduce the effectiveness of vaccines. The impact of ocrelizumab treatment on coronavirus vaccines is unknown. N...
The purpose of this study is to see if patients on ocrelizumab (Ocrevus) make antibodies in response to the coronavirus vaccine. Ocrelizumab depletes B-lymphocytes and has the potential to reduce the effectiveness of vaccines. The impact of ocrelizumab treatment on coronavirus vaccines is unknown. Natalizumab (Tysabri) likely has a minimal impact the efficacy of vaccines. In this study the investigators will take blood samples in patients being treated with either ocrelizumab or natalizumab before and after vaccination with an FDA-authorized coronavirus (COVID-19) vaccine and compare the antibody response in both groups.
Tracking Information
- NCT #
- NCT04837651
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Joshua Katz, M.D. Dragonfly Research, LLC
Get Well Soon